Prognostic value of the immunohistochemistry markers CD56, TTF-1, synaptophysin, CEA, EMA and NSE in surgically resected lung carcinoid tumors.
immunohistochemistry markers
neuron-specificenolase
pulmonary carcinoids
synaptophysin
thyroid transcription factor 1
Journal
Molecular and clinical oncology
ISSN: 2049-9469
Titre abrégé: Mol Clin Oncol
Pays: England
ID NLM: 101613422
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
12
10
2021
accepted:
24
11
2021
entrez:
5
1
2022
pubmed:
6
1
2022
medline:
6
1
2022
Statut:
ppublish
Résumé
Lung carcinoid tumor is a type of neuroendocrine tumor, which is subdivided into typical carcinoid (TC) and atypical carcinoid (AT), based on the rate of mitosis and the presence of necrosis. Several prognostic factors for lung carcinoids have been reported in the literature, including the type, Ki67 index, stage, chemotherapy and radiation therapy. In the present study, 108 cases with resected carcinoid lung tumors were enrolled and the expression of CD56, thyroid transcription factor 1, synaptophysin, carcinoembryonic antigen, epithelial membrane antigen and neuron-specific enolase (NSE) in the resected tissue specimens was immunohistochemically analyzed. Patients with positive staining for NSE had an unfavorable survival prognosis compared with patients with negative staining for NSE (137.2 vs. 150.0 months, P=0.044). According to univariate analysis, none of the above immunohistochemistry markers was associated with survival, and according to multivariate analysis, NSE was an independent influencing factor for survival inpatients with AT (P=0.046) and furthermore, the stage was an independent factor of survival in patients with TC (P=0.005).
Identifiants
pubmed: 34984102
doi: 10.3892/mco.2021.2464
pii: MCO-16-2-02464
pmc: PMC8719249
doi:
Types de publication
Journal Article
Langues
eng
Pagination
31Informations de copyright
Copyright: © Georgakopoulou et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Eur J Nucl Med Mol Imaging. 2016 Jun;43(6):1040-6
pubmed: 26611427
Ochsner J. 2017 Winter;17(4):335-340
pubmed: 29230118
Rom J Morphol Embryol. 2017;58(4):1409-1415
pubmed: 29556635
Zhongguo Fei Ai Za Zhi. 2017 Aug 20;20(8):522-527
pubmed: 28855032
PLoS One. 2014 Aug 15;9(8):e105094
pubmed: 25126747
Anticancer Res. 2008 Jan-Feb;28(1B):507-13
pubmed: 18383893
Eur J Cardiothorac Surg. 2014 Mar;45(3):521-6; discussion 526
pubmed: 24092506
J BUON. 2008 Jan-Mar;13(1):93-6
pubmed: 18404793
Cancer Res. 1994 Jun 1;54(11):2908-13
pubmed: 8187076
Acta Oncol. 2018 Aug;57(8):1109-1116
pubmed: 29463166
Ann Oncol. 2001 Sep;12(9):1295-300
pubmed: 11697843
J Clin Pathol. 1990 Aug;43(8):696-7
pubmed: 2401743
J Thorac Oncol. 2015 Sep;10(9):1243-1260
pubmed: 26291008
Cancers (Basel). 2018 Dec 12;10(12):
pubmed: 30545054
Oncotarget. 2016 May 3;7(18):26823-36
pubmed: 27072585
Cancer. 1986 Sep 15;58(6):1316-20
pubmed: 3742456
Arch Pathol Lab Med. 2010 Nov;134(11):1628-38
pubmed: 21043816
Urology. 2003 Aug;62(2):368-73
pubmed: 12893366
Turk Patoloji Derg. 2015;31(3):163-74
pubmed: 26456962
Neoplasma. 1991;38(4):433-7
pubmed: 1922575
Cureus. 2020 Sep 7;12(9):e10300
pubmed: 32923302
J Histochem Cytochem. 2017 Dec;65(12):687-703
pubmed: 28972818
J Thorac Dis. 2012 Oct;4(5):490-6
pubmed: 23050113
Radiographics. 1999 May-Jun;19(3):707-36
pubmed: 10336200
Diagn Pathol. 2020 May 19;15(1):59
pubmed: 32429938
Oncotarget. 2016 Nov 1;7(44):71727-71736
pubmed: 27687592
Cancer Med. 2018 Jun;7(6):2434-2441
pubmed: 29733505
Diagn Interv Radiol. 2019 Jul;25(4):270-279
pubmed: 31295144
Br J Cancer. 1996 Aug;74(3):463-7
pubmed: 8695366
BMC Urol. 2008 Dec 30;8:21
pubmed: 19115997
Tumour Biol. 2015 Sep;36(10):7717-23
pubmed: 25935537
Respir Med. 2004 Apr;98(4):357-62
pubmed: 15080079
Cancer. 2001 Oct 15;92(8):2204-10
pubmed: 11596039